Article Text

other Versions

PDF
Restless legs syndrome in patients with type 2 diabetes: effectiveness of pramipexole therapy
  1. Shin-Ichi Harashima1,2,
  2. Akiko Nishimura3,
  3. Tomoaki Osugi1,2,
  4. Yu Wang1,
  5. Yanyan Liu1,
  6. Hiroshi Takayama2 and
  7. Nobuya Inagaki1
  1. 1Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan
  2. 2Department of Internal Medicine, Takashima Citizen Hospital, Takashima, Japan
  3. 3Department of Human Health Science, Graduate School of Medicine, Kyoto University, Kyoto, Japan
  1. Correspondence to Dr Shin-Ichi Harashima, Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan; harasima{at}metab.kuhp.kyoto-u.ac.jp

Abstract

Objective We investigated the prevalence of restless legs syndrome (RLS) in Japanese patients with type 2 diabetes and assessed the efficacy of pramipexole therapy.

Design One hundred patients with type 2 diabetes without secondary causes of RLS were sequentially screened for the 12-week, prospective, single arm study. RLS was screened by essential diagnostic criteria developed by the International Restless Legs Study Group. Diabetic neuropathy was diagnosed by nerve conductance study. Severity of RLS and sleep quality were assessed by the International Restless Legs Rating Scale (IRLS) and the Japanese version of the Pittsburgh Sleep Quality Index (PSQI-J), respectively. Pramipexole was administered for 12 weeks. The primary end point was change in the IRLS score in 12 weeks and secondary end points were change in PSQI-J and glycated haemoglobin (HbA1c) in 12 weeks.

Results RLS was diagnosed in 8 of 100 participants (8%). Diabetic neuropathy was most likely associated with RLS (OR 3.81, 95% CI 0.85 to 17.05, p=0.111). The IRLS score was improved from 19.0±5.6 to 5.4±4.8 by pramipexole in 12 weeks (p<0.001). The change in the score was −13.6 (95% CI −15.5 to −11.7; p<0.05). PSQI-J was improved from 6.0±4.4 to 1.5±1.3 in 12 weeks (p<0.05). Change in PSQI-J was −4.5 (95% CI −6.8 to −2.1; p<0.05). HbA1c was slightly decreased from 7.19±0.56% (55±6 mmol/mol) to 6.90±0.48% (52±5 mmol/mol) in 12 weeks (p<0.05). Change in HbA1c was −0.29% (−3 mmol/mol) (95% CI −0.37% to −0.20% (−4 to −2 mmol/mol;) p<0.05).

Conclusions We find that type 2 diabetes is a possible risk factor for RLS in the Japanese population, and that pramipexole treatment can improve the symptoms of RLS as well as the quality of sleep and glycaemic control in these patients.

Trial registration number University hospital Medical Information Network in Japan (UMIN000008347).

  • Metabolic disorders
  • Neurological conditions
  • Quality of life
  • Drug administration
  • Received 30 March 2014.
  • Revision received 14 August 2014.
  • Accepted 31 August 2014.

Statistics from Altmetric.com

  • Received 30 March 2014.
  • Revision received 14 August 2014.
  • Accepted 31 August 2014.
View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.